Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma Interventions:   Biological: Anetumab Ravtansine;   Biological: Bevacizumab;   Drug: Paclitaxel Sponsor:   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials